Bright Minds Biosciences Inc.
DRUG
Clasificación en acciones
#12683
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics... Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Precio por acción
$52.67
Capitalización bursátil
$519.58M
Cambio (1 día)
4.43%
Cambio (1 año)
-13.15%
País
US
Comercio Bright Minds Biosciences Inc. (DRUG)
Categoría
Healthcare
Historial del precio de la acción de Bright Minds Biosciences Inc. (DRUG)
Precio más alto de cierre: $53.83 el 2026-10-01
Precio más bajo de cierre: $33.56 el 2021-02-01
Precio más bajo de cierre: $33.56 el 2021-02-01
Historial del precio de la acción de Bright Minds Biosciences Inc. desde 2021 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2026 (TTM) | -8.79% |
| 2025 | 105.52% |
| 2024 | 2,581.73% |
| 2023 | -68.72% |
| 2022 | -73.66% |
| 2021 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
